Log In
Print
BCIQ
Print
Print this Print this
 

AEZS-134

  Manage Alerts
Collapse Summary General Information
Company Aeterna Zentaris Inc.
DescriptionMAP kinase 3 (MAPK3; ERK-1) and ERK-2 inhibitor
Molecular Target MAP kinase 3 (MAPK3) (ERK-1) ; MAP kinase 1 (MAPK1) (ERK-2)
Mechanism of ActionMAP kinase (p38) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today